Daclatasvir
Paul G. Auwaerter, M.D., Janessa M. Smith, PharmD, BCPS
INDICATIONS
INDICATIONS
INDICATIONS
FDA
FDA
- Treatment of chronic hepatitis C virus (HCV) genotype 1 or 3 infection, in combination with sofosbuvir (SOF).
- Daclatasvir is indicated for treating HIV/HCV co-infected patients in patients with compensated Child-Pugh Class A cirrhosis, decompensated Child-Pugh B or C cirrhosis, and in patients that develop recurrent HCV post-transplant.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
Treatment of HCV genotypes 2, 4.
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2025 Unbound Medicine, Inc. All rights reserved
All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.